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ABSTRACT
CXCL16 is an interferon-inducible chemokine of the CXC-subfamily and functions as an
adhesion molecule, when membrane bound, and a chemoattractant when soluble. Upregulation
of cell associated CXCL16 (cCXCL16) in colorectal cancer is associated with increased tumor
infiltrating lymphocytes and good prognosis. ADAM10 and ADAM17 are metalloproteinases
responsible for cleaving CXCL16, releasing soluble CXCL16 (sCXCL16) and contributing to
proliferation and migration of mesangial cells, in kidney inflammatory disease. We hypothesize
that cCXCL16 is a substrate for ADAM10 and ADAM17 cleavage in colorectal cancer, releasing
sCXCL16, which mediates cell proliferation. To this end, we first identified CXCL16 in the
human colon carcinoma cell line, RKO, by immunohistochemistry. cCXCL16 was found in the
membrane, cytoplasm and nucleus. We treated RKO, in vitro, with an inflammatory cytokine
mix containing 1.4 nM rhIFNγ, 2.0 nM rhTNFα and 2.0 nM rhIL1β to increase the cleavage of
cCXCL16 to sCXCL16. Overnight incubation with the cytokine mix significantly (P=.004)
increased the release of sCXCL16 compared to normal conditions. To confirm that a
metalloproteinase is responsible for the cleavage of cCXCL16, we used a broad spectrum
metalloproteinase inhibitor, GM6001, in combination with inflammatory stimulation, in cell
culture. We assayed the supernatant using ELISA for sCXCL16. GM6001 at 100 µM decreased
sCXCL16 to levels indistinguishable from the background. Using siRNA, we knocked down the
expression of ADAM10 and ADAM17, independently, to determine if the activity of each on
cCXCL16 was mediated by inflammatory stimulation. It was shown that ADAM10
constitutively cleaved cCXCL16, and ADAM17 cleavage activity was induced by inflammatory
stimulation. To determine if sCXCL16 increased colorectal cancer cell (CRC) proliferation
iii

through ligand-receptor binding, we treated cells with a range of rhCXCL16 from 3.125-100
ng/mL. rhCXCL16 did not increase RKO proliferation at doses up to 100 ng/mL. We used
GM6001, to inhibit the cleavage of cCXCL16 into sCXCL16 then performed an ATPase assay
and 6 day cell cycle analysis, under inflammatory stimulation. Increased cleavage of cCXCL16
induced by inflammatory stimulation with the cytokine mix containing 1.4 nM rhIFNγ, 2.0 nM
rhTNFα and 2.0 nM rhIL1β, increased RKO proliferation and reduced apoptosis. We conclude
that ADAM10 and ADAM17 cleavage of cCXCL16 to sCXCL16 is increased by ADAM17
activation with inflammatory stimulation. The cleavage of the extracellular portion from
cCXCL16 is associated with increased proliferation and decreased apoptosis of colorectal cancer
cells.
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INTRODUCTION
Inflammation marks the transition between the innate and adaptive immune response, when
macrophages and neutrophils secrete cytokines and chemokines responsible for moderating
cellular activities and recruiting cells expressing the appropriate receptors 1. Antigen presenting
cells (APCs) travel back to lymph nodes and the splenic red pulp where B cells are activated and
T cells expressing antibodies specific to peptides found on the surface of APCs, are cloned.
Inflammation has been associated with cancer since Virchow observed leukocytes in neoplastic
tissue 150 years ago 2. These tumor infiltrating leukocytes are recruited through ligand-receptor
interactions directed by chemokine gradients In 2003, it had been determined that almost 25% of
all cancer cases worldwide were attributable to chronic infection and inflammation, according to
B. Stewart and P. Kleihues World Cancer, Report (2003). CXCL16 is an inflammatory
chemokine and known participant in the transition between the innate and adaptive immune
response by recruiting CD4+, CD8+ T cells and NKT cells, which express the cell surface
receptor CXCR6 3, 4.The known biological functions of CXCL16 appear to be mitigated by posttranslational proteolytic processing. While expressed as a membrane-bound protein, CXCL16
acts as an adhesion molecule, forming tight junctions through ligand-receptor binding. In this
manner, CXCL16 expressed on dendritic cells supports the adhesion of T cells in splenic red
pulp 5. After cell surface shedding into soluble form, CXCL16 is chemotactic for cells involved
in the immune response, vascular endothelial cells 6 and human mesangial cells 7, expressing
CXCR6. CXCL16 has been found up-regulated in inflammatory disease and cancer and
positively correlated to increased leukocyte trafficking, aggressiveness and metastasis of tumor
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cells7 4, 8-10. Cell associated CXCL16 has been associated with good prognosis and increased
tumor infiltrating lymphocytes in colorectal cancer 4suggesting that CXCL16 expression may be
prognostic for patient survival; however the role of CXCL16 in cancer progression is not fully
understood.
ADAM10 and ADAM17 are α-secretases that shed cell surface molecules by proteolytic
cleavage. This cleavage releases c-terminal fragments (CTFs) that are further processed by βand γ-secretases. ADAM10 and ADAM17 shed CXCL16 from the cell membrane into the
soluble form releasing CTFs of unknown function11. In some inflammatory proliferative diseases
and cancers the sheddase activity of ADAM10 and ADAM17 on CXCL16, specifically, has been
linked to increased tumor cell invasiveness and migration, as well as T cell chemotaxis,
proliferation, and migration7, 8, 10. In addition, CXCL16 promotes chemotaxis, proliferation and
tube formation in human vascular endothelial cells6. Cell associated CXCL16 has been shown to
decrease and inhibit proliferation in human mammary and colon carcinomas and pancreatic
ductal adenocarcinomas, whereas soluble CXCL16 (sCXCL16) has been shown to increase
proliferation10, 12. Inhibiting the expression of CXCL16, ADAM10 and ADAM17 has been
shown to arrest mesangial cell proliferation under inflammatory stimulation7.
Stimulation of pancreatic ductal cells with exogenous sCXCL16, under normal
conditions, does not increase cell proliferation10. Also, inhibiting the expression of CXCL16,
ADAM10 and ADAM17 or CXCL16 alone, under normal conditions, does not significantly
affect proliferation7. Mouse colon cancer cells already expressing CXCL16 do not show a
notable increase in proliferation when stimulated with exogenous sCXCL1612. These data
suggest that the function of CXCL16 in cancer cell proliferation, under inflammatory
2

stimulation, is determined by the shedding of sCXCL16 from the cell membrane. Therefore, we
tested ADAM10 and ADAM17 sheddase activity as a mediating event in human colon cancer
cell proliferation, using in vitro studies with the human colon cancer cell line RKO. Our results
suggest that the increase in colon cancer cell proliferation is not the result of autocrine signaling
through ligand-receptor binding of sCXCL16, but through intercellular signaling by the CTF also
released by ADAM10 and ADAM17 shedding. The release of sCXCL16 has the added effect of
decreasing apoptosis. Our data suggest that CXCL16 may be a novel target for reducing
proliferation and increasing apoptosis in colon cancer.
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MATERIALS AND METHODS
Identification of cell-associated CXCL16
Materials
Human colon carcinoma cell line, RKO, was purchased from ATCC, and cultured in
vented cap T-75 tissue culture flasks (NUNC) in EMEM supplemented with 10% heat
inactivated FBS (GIBCO/Life Technologies) and 1% Penicillin-Streptomycin (GIBCO/Life
Technologies) in a humidified incubator with 5% CO2 at 37˚ C. Cells expressing CXCL16 were
identified by ICC using an anti CXCL16 (C-20) goat polyclonal IgG antibody (Santa Cruz).
Immunocytochemistry was performed on cells fixed to precleaned glass microscope slide cover
slips (VWR) using 4% paraformaldehyde solution.

Reagents and solutions
4% Paraformaldehyde solution
While 80 mL of autoclaved distilled water was heated to 60⁰C, 4 grams of
paraformaldehyde was added as solution stirred. The solution was covered and allowed to come
up to temperature. 10 N NaOH was added drop wise until solution cleared: approximately 10
drops. 4 mL of 25X PBS was added to bring volume to 100 mL. pH was adjusted to 7.0 using
HCl. Solution was sterilized using vacuum filtration and stored in a light sensitive bottle.
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Peroxidase quencher
Peroxidase quencher was made in PBS with a final concentration of 3% peroxide and 1%
sodium azide.

PBST
2 mL Tween-20 was dissolved in 800 mL PBS. The pH was adjusted to 7.2, and then the
solution was autoclaved.

SDS
.5 grams SDS was added to 50 mL PBS and the solution was stirred until clear.

10% BSA
5 grams of BSA was dissolved in PBS to a final volume of 50 mL.

0.1% LiCO3
.05 grams of LiCO3 was dissolved in 50 mL autoclaved distilled water.

Fixed cell preparation
250,000 cells were plated on glass cover slips placed in each well of a 6 well plate. Cells
were grown to confluence in 2 mL EMEM full growth media until cells reached confluence.
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Immunocytochemistry
All steps were performed with cover slips in 6 well plates. Full growth media was
removed and cells were washed and incubated for 1 minute; two times with ice cold PBS. Cells
were fixed for 10 minutes in 1 mL of 4% paraformaldehyde, then washed and incubated for 2
minutes; three times with PBST. Cells were then dehydrated by 5 minute incubations with
increasing concentrations of methanol (25%, 50%, 75% and 100%). Antigen retrieval was
performed by washing fixed cells three times, in PBS for 5 minutes each, then incubating in 1%
SDS for 5 minutes and finally washing three times for 5 minutes in PBS. Peroxidase activity was
quenched with a 15 minute incubation in peroxidase quencher. Fixed cells were blocked in 10%
BSA for 30 minutes, and then blocking agent was removed. Cells were incubated for one hour at
room temperature in primary antibody specific for an epitope on the internal portion of CXCL16
(Santa Cruz) at a 1:50 concentration. Primary antibody was removed after one hour and cells
were washed three times for five minutes in PBS. Cells were incubated for 1 hour at room
temperature in secondary antibody, anti-goat-HRP (Santa Cruz) at a 1:100 concentration.
Secondary antibody was removed after one hour and cells were washed three times for 5 minutes
in PBS Color was developed with a 5 minute incubation in DAB. After incubation cells were
washed 2 times in tap water. Counter staining was performed with a 5 minute incubation in
hematoxylin. After incubation the hematoxylin solution was removed. The cells were washed
two times in tap water, dipped in 3% acid-alcohol (Sigma), washed one time in tap water then
dipped in LiCO3. Fixed cells were then dehydrated by incubating for three times in 100%
methanol for 5 minutes then incubating three times in 100% xylene for 5 minutes. Glass cover
slips were mounted on precleaned glass microscope slides (Fisher Scientific). Digital images
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were taken using a camera (Leica DFC300 FX) mounted on a light microscope (Nikon Eclipse
E400).

Induced increase in soluble CXCL16 in cell culture
Materials
The inflammatory cytokine mix 7 containing 1.4 nM rhIFNγ (R & D Systems), 2 nM
rhTNFα (R & D Systems) and 2 nM rhIL1β (R & D Systems). Conditioned media was assayed
for soluble CXCL16 using a premade Quantikine Human CXCL16 ELISA kit (R & D Systems),
according to the manufacture’s instructions.

Cell culture preparation
RKO cells were plated in 100 cm tissue culture dishes (BD Biosciences) at the
concentration of 4 million cells in 5 mL of full growth media. The cells were allowed to adhere
in a humidified incubator with 5% CO2 at 37˚C overnight. After incubation the media was
removed, the cells were washed two times with DPBS, and the media was changed to include the
inflammatory cytokine mix (1.4 nM rhIFNγ, 2 nM rhTNFα and 2 nM rhIL1β). Cells were
allowed to incubate in a humidified incubator with 5% CO2 at 37˚C for either 15 minutes or
overnight. Control cells were plated, incubated 15 minutes or overnight in full growth media that
did not include the inflammatory cytokine mix. After incubation, the conditioned media was
removed, centrifuged to remove any debris then assayed for soluble CXCL16.
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ELISA
All samples were assayed in quadruple. A Quantikine Human CXCL16 ELISA was
purchased from R & D Systems (Minneapolis, MN). All buffers and reagents were brought to
room temperature before assay was performed. The CXCL16 standard was reconstituted with 1
mL autoclaved distilled water to a stock concentration of 100 ng/mL. Serial dilutions were made
using the provided Calibrator Diluent RD5R to final working concentrations of 10 ng/mL, 5
ng/mL, 2.5 ng/mL, 1.25 ng/mL, 0.625 ng/mL, 0.315 ng/mL and 1.156 ng/mL. The Calibrator
Diluent was used as the zero standard. 100 mL of the provided 100µl Assay Diluent RD1W was
added to each well. 50 µl of each standard and sample was added to individual wells. After 2
hours incubation at room temperature, the solutions were removed and the wells were washed
four times with 300 µl of the provided wash buffer. After the fourth wash 200 µl of the provided
conjugate was added to each well and incubated for two hours at room temperature. After the
incubation the solutions were removed and the plate was washed four times with 300 µl of the
provided wash buffer. After the fourth wash 200 µl of the provided substrate solution was added
to each well in incubated for 30 minutes at room temperature protected from light. After the
incubation 50 µl of the provided stop solution was added to each well and the absorbance
intensity was read using a microplate reader (FLUOstar OPTIMA).
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Optimization of GM6001 broad spectrum metalloproteinase inhibitor
Materials
The broad spectrum metalloproteinase inhibitor, GM6001 (Sigma) was used to
inhibit ADAM10 and ADAM17 proteolytic activity. The inflammatory cytokine mix containing
1.4 nM rhIFNγ (R & D Systems), 2 nM rhTNFα (R & D Systems) and 2 nM rhIL1β (R & D
Systems) was used to sCXCL16 concentrations in the cell culture supernatant. Conditioned
media was assayed for soluble CXCL16 using a premade Quantikine Human CXCL16 ELISA
kit (R & D Systems), according to the manufacture’s instructions.

Determining sCXCL16 concentration using ELISA
250,000 RKO cells were plated in 6 well plates in full growth media and incubated
overnight in a humidified incubator at 37˚C in 5% CO2, to allow cells to adhere. After
incubation, the media was removed and the cells were washed 2 times with DPBS. Cultures were
then incubated in increasing concentration of GM6001 (Sigma): 25 µM, 50 µM, 100 µM, 200
µM and 400µM for 15 minutes, then 2 mL of full growth media with the addition of the
inflammatory cytokine mix was added to the wells and the plates were incubated overnight in a
humidified incubator at 37˚C in 5% CO2. After incubation, culture media was removed and
centrifuged to remove debris and assayed for sCXCL16 using a premade Quantikine Human
CXCL16 ELISA kit (R&D Systems) as previously described. All conditions were performed in
triplicate. All samples were assayed in duplicate.
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Determining the role of ADAM10 and ADAM17 in cCXCL16 cleavage into sCXCL16
Materials
siRNA duplexes were purchased from Invitrogen (Carlsbad, CA). The sequences are as
follows: ADAM10 5’ AGA CAU UAU GAA GGA UUA UTT 3’; ADAM17 5’ GAG AAG
CUU GAU UCU UUG CTT 3’; and a scrambled control 5’ AGG UAG UGU AAU GCG CUU
GTT 3’. Cells were tranfected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions and using electroporation with a GenePulser Xcell with Shockpod
(BioRad).

Optimization of knockdown
500,000 cells were treated with differing concentrations of siRNA duplexes.
Transfections were carried out using Lipofectamine 2000 (Invitrogen). Different picomole
concentrations of siRNA were diluted in 25 µl of Opti-MEM I Medium, and mixed gently. 10 µl
of Lipofectamine 2000 was diluted into 25 µl of Opti-MEM I Medium (Invitrogen) and
incubated at room temperature for 5 minutes. After incubation, the diluted Lipofectamine 2000
was added to 6 well plates with the diluted RNAi complexes, mixed gently, and incubated for 15
minutes at room temperature. After incubation, cells were added to the well and the media
volume was brought up to 1 mL using Opti-MEM I Medium. Cells were incubated overnight in a
humidified incubator at 37˚C with 5% CO2. After overnight incubation, the media was removed,
the cells were washed 2 times with DPBS and 1 mL of EMEM full growth media was added.
After overnight incubation in a humidified incubator at 37˚C with 5% CO2 the media was
10

collected for use in ELISA. This procedure was repeated with the exception that cells were
transfected by electroporation at 300V and 960µF with a GenePulse Xcell (BioRad). ELISA was
performed on cell culture supernatant to assay for sCXCL16 using a premade Quantikine Human
CXCL16 ELISA kit (R&D Systems) as previously described. Effective knockdown was
determined through RNA analysis using qRT-PCR of cDNA reverse transcribed from tcRNA
extracted from cell pellets.

sCXCL16 after ADAM10/ADAM17 knockdown under non-inflammatory and
inflammatory conditions
500,000 cells for each condition were electroporated at 300V and 960µF with
predetermined concentrations of siRNA duplexes for ADAM10, ADAM17 and equivalent
concentration of scramble siRNA duplexes. Cells were plated in 6 well plates in 1 mL media and
incubated overnight in a humidified incubator at 37˚C with 5% CO2. After overnight incubation,
the media was removed, the cells were washed 2 times with DPBS and 1 mL of fresh media was
added. This procedure was repeated with the addition that the fresh media contained the
inflammatory cytokine mix including: 1.4 nM rhIFNγ (R & D Systems), 2 nM rhTNFα (R & D
Systems) and 2 nM rhIL1β (R & D Systems). Each condition was plated in triplicate. sCXCL16
was quantified using a premade Quantikine Human CXCL16 ELISA kit (R & D Systems) as
previously described. Knockdown was determined using qRT-PCR, as previously described.
Wild type RKO cell culture was used as a control. GAPDH was used as the endogenous gene
expression control.
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Comparison of proliferation in sCXCL16 versus cCXCL16
Materials
Proliferation was measured using the ATPase assay, Cell Titer Glo (Promega).
Luminescence intensity was measured using a microplate reader (FLUOstar OPTIMA). GM6001
(Sigma) was used to inhibit ADAM10 and ADAM17 activity to increase cCXCL16.

Growth curve for optimal plating density
RKO cells were plated, in quadruple, in white walled 96 well plates (Lonza) at 500
cells/well, 1500 cells/well, 4500 cells/well, 13,500 cells/well and 40,500 cells/well, in 100 µl of
full growth media. Each cell concentration was plated for a reading at a 0 time point to establish
a baseline, 2 days, 4 days and 6 days. 100 µl of reconstituted cell titer glo reagent was added to
each well and incubated protected from light at room temperature to ensure complete lysis and
allow optimal luminescence intensity. The plate was incubated in a humidified incubator at 37˚C
in 5% CO2 in between time points.

Measuring the effect of cCXCL16 on proliferation
EMEM full growth media was made including 100 µM GM6001. Cells were trypsinized
from culture, pelleted and resuspended in 1 mL DPBS with the addition of 100 µM GM6001,
allowed to sit for 15 minutes then counted. 1000 cells were plated in wells of a 96 well plate
using 100 µl of full growth media containing 100µM GM6001. Full growth media containing
GM6001 was plated without cells as a background luminescence control. 100 µl of cell titer glo
12

reagent was added to the wells then incubated for 15 minutes at room temperature.
Luminescence was quantified on a microplate reader (FLUOstar OPTIMA). Each experimental
condition was plated in triplicate. Each condition was assayed on days 1 - 7. These experimental
conditions were repeated with the additional treatment of the inflammatory cytokine mix.

Measuring the effect of sCXCL16 on proliferation
Cells were trypsinized from culture, pelleted, resuspended in 1 mL DPBS and counted.
1000 cells were plated in wells of a 96 well plate using 100 µL of full growth media. Full growth
media was plated without cells as a background luminescence control. 100 µl of cell titer glo
reagent was added to the wells then incubated for 15 minutes at room temperature.
Luminescence was quantified on a microplate reader (FLUOstar OPTIMA). Each experimental
condition was plated in triplicate. Each condition was assayed on days 1 - 7. These experimental
conditions were repeated without the additional treatment of the inflammatory cytokine mix.

Measuring the effect of exogenous sCXCL16 on proliferation
Aliquots of EMEM full growth media including 100 µM GM6001 were made with the
following concentration of rhCXCL16 to simulate stimulation of cells by exogenous soluble
CXCL16: 3.125 ng/mL, 6.25 ng/mL, 12.5 ng/mL, 25 ng/mL, 50 ng/mL and 100 ng/mL. One
aliquot contained no rhCXCL16 for use as a control. Cells were trypsinized from culture,
pelleted and resuspended in 1 mL DPBS with the addition of 100 µM GM6001, allowed to sit for
15 minutes then counted. 1000 cells were plated in wells of a 96 well plate using 100 µl of the
media aliquots containing rhCXCL16 100 µl of media only was plated as a background control.
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100 µl of cell titer glo reagent (Promega) was added to the wells then incubated for 15 minutes at
room temperature. Luminescence was quantified on a microplate reader (FLUOstar OPTIMA).
Each experimental condition was plated in triplicate. Each condition was assayed on days 1 – 7.

Determining the effect of sCXCL16 vs. cCXCL16 on proliferation and apoptosis under
inflammatory conditions
Materials
FACS Caliber (BD Biosciences) was used to perform the cell cycle analysis

Reagents and solutions
PI stain
To make 50 mL, 59 mg sodium citrate, 2.5 mg propidium iodide and 50 µl Triton X were
mixed. Autoclaved deionized water was added for a total volume under 50 mL. The solution was
brought to pH 7.8 and then 150 µl of RNase 1was added. Autoclaved deionized water was added
to a total volume of 50 mL.

Staining protocol
Cells were fixed in 70% ethanol. After fixing, cells were washed in PBS and PI stain was
added in the dark while vortexing.
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Proliferation under inflammatory stimulation determined by ATPase assay
1,000 cells were plated in wells of a 96 well plate in 100 µl of EMEM full growth media
with the addition of the inflammatory cytokine mix containing: 1.4 nM rhIFNγ (R & D Systems),
2 nM rhTNFα (R & D Systems) and 2 nM rhIL1β (R & D Systems). Cells were incubated for 15
minutes with the metalloproteinase inhibitor, GM6001, and then plated in wells of a 96 well
plate in 100µl of EMEM full growth media with the addition of GM6001 and the inflammatory
cytokine mix. Full growth media and full growth media with GM6001 were plated with no cells
for use as a background luminescence control. For 6 days proliferation was determined by
adding 100 µl of cell titer glow reagent, allowing the cells to incubate at room temperature for 15
minutes and reading luminescence intensity with a microplate ready (FLUOstar OPTIMA). Each
condition was read daily for 6 days.

Apoptosis analysis under inflammatory stimulation determined by cell cycle analysis
1 million cells were plated in each well in a 6 well plate with EMEM full growth media
with the addition of the inflammatory cytokine mix containing: 1.4 nM rhIFNγ (R & D Systems),
2 nM rhTNFα (R & D Systems) and 2 nM rhIL1β (R & D Systems). Cells were incubated in a
humidified incubator at 37˚C with 5% CO2. Cells were trypsinized and collected for PI staining
and cell cycle analysis by flow cytometry, every day for 6 days, using a FACS Caliber (BD
Biosciences) The experimental conditions were repeated with the addition of the
metalloproteinase inhibitor, GM6001.
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RESULTS
CXCL16 expression in RKO
CXCL16 is one of two known chemokines which have a membrane bound form
functioning as a strong adhesion molecule for cells expressing the receptor, CXCR6 5.
Ectodomain shedding produces a soluble form of CXCL16 which is a strong chemoattractant 11.
CXCL16 was identified in the Colo205, LS174T, SW480, and T84 colon cancer cell lines as
well as human tissues resected from colon tumors by RT-PCR and immunohistochemistry using
an antibody recognizing an unidentified epitope 1. In this study, the transcription of CXCL16 in
human tumor samples was compared to transcription in the normal mucosa, grouped as weak,
intermediate and strong expressers using staining intensity with immunohistochemistry.
Transcription levels were then compared to staining intensity of CD4 +and CD8 + tumor
infiltrating lymphocytes. Colon tumor cells had higher transcription of CXCL16 than normal
mucosa and the CXCL16-strong stain intensity group had a higher incidence of TIL (tumor
infiltrating lymphocytes). CXCL16 was found to be associated with the cell membrane and the
cytoplasm. CXCL16 was also identified in a sample of 23 human rectal patients using RT-PCR,
western blotting and immunohistochemistry using an antibody recognizing an epitope on the
chemokine domain. These data showed no significant difference in transcription between tumor
cells and normal cells of the same patient, and western blotting and immunohistochemistry
showed decreased CXCL16 in tumor tissue and lysate compared to the normal tissue of the same
patient16.
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We wanted to determine if CXCL16 was expressed in the human colon cancer cell line
RKO. Understanding that CXCL16 is shed from the cell membrane, we used an antibody
targeting an epitope in the cytoplasmic domain. γ-secretases process the surface molecules,
Notch and E-Cadherin , which generate C-terminal fragments functioning as signal transmitters
11

. C-terminal fragments of CXCL16 have been found in the normal embryonic kidney cell line,

HEK293 11, suggesting that CXCL16 may require similar processing for functional activation or
perform a similar functional role as Notch or E-Cadherin. To further elucidate the potential for
CXCL16, not just as an adhesion molecule and soluble chemoattractant, but possibly as an
intracellular signaling molecule, we performed immunocytochemistry on RKO cells fixed to
glass cover slips, with an anti-CXCL16 antibody targeting a cytoplasmic epitope, to identify the
areas of the cell containing CTFs (c-terminal fragments) of CXCL16.
We identified CXCL16 on the cell membrane, in the cytoplasm, and in the nucleus of
RKO cells, as indicated by red staining (Figure 1). Protein that has performed its function or is
nonfunctional is normally targeted for degradation. These data suggest that the C-terminal
fragments of CXCL16 may perform a functional role in colorectal tumor cells. Due to the
identification of CXCL16 in RKO further studies are possible.
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Figure 1. Immunocytochemistry of RKO cells stained using anti-CXCL16 antibody.
CXCL16 can be found associated with the cell membrane, cytoplasm and nucleus of RKO
cells in culture.
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Inflammatory stimulation increases sCXCL16
Treating cells in vitro with inflammatory stimulation including TNFα and IFNγ increases
the release of sCXCL16 in astrocytes, glioma cells, endothelial cells from human umbilical vein
and smooth muscle cells, and human mesangial cells7, 8, 17. To determine if CXCL16 is shed from
the membrane of human colorectal cells, we treated RKO cells with a cytokine mix containing
2.0 nM IL-1β, 2.0 nM TNFα and 1.4 nM IFNγ 7. We used two incubation times to determine if
sCXCL16 increased over time under constant stimulation. We used ELISA to test the
concentration of CXCL16 in the cell culture supernatant after an incubation of 15 minutes and
overnight incubation. Soluble CXCL16 increases with stimulation in as little as 15 minutes after
the initial assault, however there was a significant increase of sCXCL16 (P=.004) compared to
the unstimulated control after overnight stimulation (<24 hr) (Figure 2). CXCL16 is an IFNγ –
inducible chemokine, which suggests that inflammatory stimulation would increase the
transcription of CXCL16 making more available for sheddase activity. However, posttranscriptional modifications, evidenced by the shedding of CXCL16, may be induced by this
same mechanism. Understanding the transcriptional and post-transcriptional mechanisms
involved when inflammatory stimulation increases sCXCL16 may suggest one or more targets to
mediate this activity.
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Figure 2. sCXCL16 concentrations in RKO cell culture supernatants after 15 minute or
overnight (OV) incubations with the inflammatory cytokine mix containing 1.4 nM rhIFNγ,
2.0 nM rhTNFα and 2.0 nM rhIL1β. ELISA was performed to measure the amount
(pg/mL) of sCXCL16 in RKO cell supernatant.

* indicates P=.004 using Welch’s t-test between the control and overnight cell culture
populations.
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GM6001 optimal biological dose as determined by ELISA
ADAM10 and ADAM17 are responsible for shedding of CXCL16 in human mesangial
cells 7. To investigate the role of ADAM10 and ADAM17 on the shedding of CXCL16 in human
colorectal cancer cells we confirmed that shedding of CXCL16 is achieved through
metalloproteinase activity. GM6001,a broad spectrum metalloproteinase inhibitor, obtained
lyophilized from Sigma, inhibits proteolysis of some metalloproteinases, including ADAM10
and ADAM17 7. To measure the efficacy of GM6001 to inhibit metalloproteinase cleavage of
cCXCL16 into sCXCL16 on RKO, cells were incubated with GM6001, reconstituted in DMSO,
with concentrations ranging from 25 µM to 400 µM under inflammatory stimulation. After an
initial 15 minute incubation in GM6001, cells were cultured overnight in media including
GM6001 with the addition of inflammatory cytokine stimulation. The supernatants were
collected and assayed for sCXCL16 concentrations using ELISA. Full growth media was used as
a control to identify baseline absorbance. GM6001 at 100 µM was determined to be optimal for
metalloproteinase inhibition by causing a decrease in sCXCL16 to levels indistinguishable from
background absorbance levels (Figure 3). Although higher doses of inhibitor, up to 400 µM
concentration, showed a trend in decreased detectable levels of sCXCL16, this also increased the
volume of DMSO introduced into cell culture, thereby increasing the risk of toxicity to the cells.
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Figure 3. sCXCL16 concentrations in cell culture supernatants as determined by ELISA.
RKO cells were incubated overnight in full growth media in the presence of GM6001 (25
µM - 400µM) and inflammatory stimulation with 1.4 nM rhIFNγ, 2.0 nM rhTNFα and 2.0
nM rhIL1β.

22

ADAM10 is responsible for constitutive shedding of sCXCL16
ADAM10 has been associated with the constitutive cleavage of cell membrane adhesion
molecules including CXCL16 17 18and ADAM17 has been associated with inflammatory induced
cleavage 8, 17 To determine the roles of ADAM10 and ADAM17 in shedding CXCL16 from
RKO cells we knocked down the expression of each metalloproteinase with siRNA
oligonucleotides targeting ADAM10 (labeled A10) and ADAM17 (labeled A17). Control cells
were transfected with scrambled oligonucleotides in concentrations comparable to those used for
ADAM10 and ADAM17, 750 pmol/mL (SCR 750) and 1500 pmol/mL (SCR 1500),
respectively. We measured CXCL16 proteolysis using sandwich ELISA targeting sCXCL16 in
the cell culture media. We assayed the degree of knockdown by qRT-PCR with primers specific
for ADAM10 and ADAM17 then determined the percentage of gene expression as compared to
the control using the formula 100 – [(1-2-ΔΔCT) x 100]. After overnight incubation without
inflammatory stimulation the knockdown of ADAM10 decreased sCXCL16 to levels
indistinguishable from background absorbance levels, although ADAM17 was still being
expressed (Figure 4 A). ADAM10 expression was 38.6% of the control expression level (Figure
4 C). Under non-inflammatory conditions ADAM17 expression was knocked down to 44.34% of
control levels, as ADAM10 continued to be expressed (Figure 4 C). Although the level of knock
down for ADAM17 was similar to that shown for the independent knock down of ADAM10, the
decrease of sCXCL16 was not comparable to that in the ADAM10 knockdown experiment, as
shown in Figure 4 A. These data suggest that under non-inflammatory conditions ADAM10
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sheddase activity is necessary and sufficient to account for sCXCL16 in comparison to
ADAM17.
Although we attempted to repeat these studies under inflammatory conditions, we did not
achieve the level of knockdown for either ADAM10 (2%) or ADAM17 (24%), (Figure 4 D),
compared to the scrambled controls, SCR 750 and SCR 1500, respectively. It is possible that
inflammatory conditions induce the transcription of ADAM10 and ADAM17 at a rate which
overwhelmed the siRNA ability to induce degredation of the mRNA. However, the slight
decrease in sCXCL16, as shown in Figure 4 B, suggests that ADAM17 does participate in
shedding sCXCL16 under inflammatory conditions. These data suggest that ADAM10
constitutive cleavage is not sufficient to account for all sCXCL16 released under inflammatory
conditions.
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Figure 4. sCXCL16 concentrations in cell culture supernatants determined by ELISA after
siRNA-knockdown of ADAM10 or ADAM17 under normal (A) and inflammatory (B)
stimulation. Percent (%) expression compared to the controls were determined by qRTPCR of mRNA levels after knockdown as determined by the formula 1-[(1-2-ΔΔCT)x100]
under normal (C) and inflammatory (D) stimulation.
Student t-test determined there is no significant difference in sCXCL16 concentrations
between experimental conditions and control P > 0.05.
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Optimal plating density for RKO cells
To identify the effect of CXCL16 on the proliferation of RKO cells, we measured cell
viability as determined by ATP concentration. Increased ATP levels suggest increased cellular
metabolic activity and cell number. However, limiting factors for cells in culture include growth
factor and nutrient resources, as well as growth surface area, as many cells maintain contact
inhibition. We tested for the optimal plating density for RKO cells in 96 well plates to ensure the
results of our proliferation studies were not biased due to the limiting factors named above. Cells
were plated at the lowest density of 500 cells up to 40,500 cells. Cells were cultured in 100 µl
full growth media, with no media changes for one week. We determined the optimal plating
density to be between 50 and 1500 cells per well (Figure 5). Cell culture concentrations of 1000
cells per well in a 96 well plate would allow for testing of inflammatory stimulation on
proliferation, over five days, without the deleterious effects of over-confluence and lack of media
resources for cells. These data allow us to extrapolate optimal densities for other cell growth
areas using the formula: (growth area cm2/.32 cm2) x 1000 = optimal plating density.
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Figure 5. Cell viability assay to determine optimal plating density of RKO cells in 96 well
plates. Cells were plated at different densities and on day 0, 2, 4 and 6, cell viability was
measured by Cell Titer Glo Luminescent Cell Viability Assay (cell number correlates with
luminescent output, RLU).
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Exogenous sCXCL16 does not increase RKO cell proliferation
The shedding of cell surface molecules is a regulatory mechanism necessary to mediate
biological activities such as juxtacrine, autocrine and paracrine signaling and releasing
cytoplasmic domains for intracellular signaling. CXCL16 recruits CXCR6-expressing CD4+ and
CD8+ T cells 4, and is associated with increased proliferation of murine astroglial and microglial
CXCR6-expressing cells8. CXCL16 activity occurs with a concentration of 10 ng/mL, as
measured by chemotaxis of CXCR6 expressing JURKAT cells and CXCR6 expressing CD4+,
CD8+, and NKT cells 3. To test the effect of CXCL16 on cell proliferation through ligandreceptor binding, RKO cells were incubated overnight with purchased recombinant human
CXCL16 (rhCXCL16) at concentrations ranging from 3.125 ng/mL – 100ng/mL and ATP cell
viability assay was performed. Stimulation of RKO cells with exogenous sCXCL16 in the form
of recombinant human CXCL16, did not affect the growth rate and viability of the cells (Figure
6). These data suggest that any effect CXCL16 may have on colon cancer cell proliferation does
not operate in the receptor-ligand binding mechanisms defining autocrine, paracrine or juxtacrine
signaling. It is possible that CXCL16 shedding from the cell membrane releases the cytoplasmic
portion of CXCL16 which is then involved in intracellular signaling.

28

luminescence intensity

500000

100 ng
50 ng

400000

25 ng

300000

12.5 ng
6.25 ng

200000

3.125 ng
control

100000
0
day 0

day 2

day 4

day 6

Figure 6. Proliferation measured by ATPase assay of RKO cells after treatment with
increasing concentrations of exogenous sCXCL16.
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sCXCL16 increases proliferation and decreases apoptosis compared to cCXCL16 under
inflammatory conditions
We assessed the ability of CXCL16 to affect RKO cell proliferation through intracellular
signaling. The shedding of cell surface CXCL16 is catalyzed by inflammatory stimulation that
includes IFNγ, TNFα and IL-1β. Notably, although TNFα and IFNγ alone increase the release of
sCXCL16, stimulation with these inflammatory cytokines in concert significantly increases
sCXCL16 concentrations within the same time window 13. Shedding of the extracellular portion
of cell surface molecules is necessary to release the intracellular portion11. All cultures were
treated with the inflammatory cytokine mix containing 1.4 nM rhIFNγ, 2.0 nM rhTNFα and 2.0
nM rhIL1β. Cell viability, as measured by ATP assay, was assessed every 24 hours for 6 days.
To further distinguish the shedding of CXCL16 involvement in proliferation from any treatment
effects attributable to inflammatory stimulation we performed our proliferation studies with the
additional condition of metalloproteinase inhibition, using the established optimal dose (100 µM)
of GM6001. Cells releasing sCXCL16 showed greater proliferation than cells retaining
cCXCL16, although Student’s t-test determined no significant difference, P > 0.05 (Figure 7 A).
As treatment with increased exogenous sCXCL16 did not increase proliferation in RKO cells,
our data suggest that CXCL16 plays a role in RKO cell proliferation through intracellular
signaling.
To further clarify the association of shedding CXCL16 with proliferation and thereby a
possible role in tumor growth, we repeated the above experiment using cell cycle analysis as a
means to measure proliferation and apoptosis. Cell cycle analysis was conducted by flow
cytometry of PI stained cells. Experimental conditions were compared to control cell cultures
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grown under non-inflammatory conditions and without metalloproteinase inhibition. Control cell
cycle analysis is represented in red. Experimental conditions are represented in blue. The portion
of the cell cycle analysis representing apoptotic cells (0 – 50 on the x-axis), is larger for cells
maintaining cCXCL16 compared to cells shedding sCXCL16 (Figure 7 C and D, respectively).
Graphical comparison of the apoptotic indices is represented in Figure 7 B. Cell cycle analysis
supported our ATP cell viability results and indicated that shedding of CXCL16 from the cell
membrane of RKO cells was associated with increased proliferation, as shown by an increase in
the number of cells in the population in G2 (Figure 7 D, portion of histograph with a mean of 100
on the x-axis). These data suggest that CXCL16 is an important mediator of colon cancer cell
survival and proliferation through inflammatory signaling pathways.
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Figure 7. ATPase assay and cell cycle analysis of RKO cells (A) ATPase assay showing
sCXCL16 is associated with increased RKO cell proliferation compared to cCXCL16. (B)
Apoptotic index of cell cycle analysis shows that cCXCL16 is associated with increased
RKO cell death compared to sCXCL16. (C) Cell cycle analysis of RKO cells grown in
inflammatory conditions while under GM6001 metalloproteinase inhibition and assayed
every 24 hours for 6 days after PI staining and measured using flow cytometry. (D) Cell
cycle analysis of RKO cells grown under inflammatory conditions and assayed every 24
hours for 6 days after PI staining and measured using flow cytometry.
Student t-test determined there is no significant difference in experimental conditions for
proliferation or apoptosis P > 0.05.
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CONCLUSION
We have shown that CXCL16 is involved in the proliferation and survival of colorectal cancer
cells. ADAM10 constitutively cleaves CXCL16, however inflammatory stimulation promotes
the increased release of sCXCL16 through increased ADAM17 proteolysis. The shedding of cell
surface CXCL16 is necessary to initiate functional activity related to increased proliferation and
survival under inflammatory conditions. As increased proliferation and decreased apoptosis is
not evidenced with increased soluble CXCL16 alone, our data suggest these effects do not result
from ligand-receptor signaling. CXCL16 is constitutively cleaved by ADAM10, however
increased cleavage through ADAM17 proteolysis suggests a threshold must be reached to
overwhelm competing signals or that CXCL16 is only one among other molecules up-regulated
by inflammatory stimulation working in concert to increase survival and growth.
Although it is known that CXCL16 is expressed as a cell surface molecule with an
extracellular, transmembrane and cytoplasmic domain 13, we attempted to detect cell associated
fragments of CXCL16, specifically by targeting an epitope on the cytoplasmic domain. Cterminal fragments (CTFs) released after the cell surface portion of CXCL16 is shed are not
immediately degraded and have been detected in cell lysates 11. As cells degrade proteins that are
no longer useful, we speculated that the CXCL16 CTFs previously identified may function in
intracellular signaling. Our immunocytochemical analysis revealed that CXCL16 CTFs are
found in the cytoplasm and associated with the nucleus thereby suggesting further analysis of
CXCL16 biological activity may be revealing.
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ELISA analysis of sCXCL16, after inflammatory stimulation with a cytokine mix
containing IL-1β, TNFα and IFNγ, determined that inflammation increases CXCL16 shedding,
and sCXCL16 concentrations increase with continued inflammatory stimulation (Figure 2). It has
been shown that ADAM10 and ADAM17 are responsible for the shedding of sCXCL16 from the
cell surface7, 11, 17, 19. Using siRNA to knockdown the expression of ADAM10 and ADAM17
under normal and inflammatory conditions, we found that a decrease in ADAM10 expression to
less than half of normal expression levels (Figure 4 C) precluded the detection of sCXCL16
(Figure 4 A), supporting the role of ADAM10 in constitutive cleavage of cell associated
CXCL16. Knockdown of ADAM17 to less than half of normal expression levels (Figure 4C) did
not significantly decrease sCXCL16 levels (Figure 4 A), indicating that ADAM17 does not have
a significant role, if any, in the cleavage of CXCL16 under normal conditions. The knockdown
experiments under inflammatory stimulation were not conclusive. However, less than 30%
knockdown of ADAM17 (Figure 4 D) from normal expression levels did result in a slight
decrease in sCXCL16 (Figure 4 B). These data in conjunction with our ELISA data of increased
sCXCL16 with inflammatory stimulation, as well as data from previous studies that determined
ADAM17 cleaves human mesangial cells under inflammatory stimulation7, suggest ADAM17
participate in CXCL16 cleavage in colorectal cancer cells under inflammatory stimulation.
Autocrine, paracrine and juxtacrine signaling occurs though ligand-receptor binding. The
chemotactic and cell adhesion functions of CXCL16 occur through paracrine 20 and juxtacine
signaling 5, 21, 22, respectively. We determined that CXCL16 signaling in proliferation does not
occur through ligand-receptor binding in the human colon cancer cell line RKO. Stimulation of
RKO with increasing concentrations of sCXCL16 in the form of recombinant human CXCL16
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(rhCXCl16) did not increase proliferation (Figure 6), although we confirmed the natural ligand,
CXCR6, is expressed by RKO cells, using RT-PCR and western blot analysis (data not shown).
However, increased sCXCL16 associated with increased cleavage of cell associated CXCL16
(cCXCL16), induced by inflammatory stimulation, positively correlated with RKO cell
proliferation (Figure 7A) and decreased apoptosis (Figure 7 B). The extracellular domain of
CXCL16, which contains a chemokine domain chemotactic for cells expressing the receptor
CXCR6 3, 5, 721, is shed from the cell membrane due to proteolytic cleavage attributed to the
metalloproteinases ADAM10 and ADAM17 7, 8, 11, 17, 19,as metalloproteinase inhibition prevents
cCXCL16 proteolysis into sCXCL16. In addition, inhibition of cCXCL16 shedding into
sCXCL16 with broad spectrum metalloproteinase inhibitors precludes proliferation and the antiapoptotic effect of increased sCXCL16 associated with inflammatory stimulation.
CXCL16 has been shown to increase proliferation of human umbilical vein endothelial
cells through ligand receptor binding, although this effect is not as significant when cells are
stimulated with bFGF8. However, knockdown of CXCR6 in human colon carcinoma cells
showed significantly increased proliferation12. While stimulation of wild type colon carcinoma
cells with soluble CXCL16 showed slight increase in proliferation, pancreatic tumor cells with
knocked down expression of endogenous CXCL16 showed a 50% increase in proliferation when
stimulated with exogenous soluble CXCL1612. We cannot ignore that these data suggest that
there is another signaling mechanism, other than CXCL16-CXCR6 axis signaling, by which
CXCL16 functions to increase proliferation. Using iPSort, we performed an analysis of the
CXCL16 protein sequence using the FASTA sequence and found a nuclear localization signal
characterized by a leucine rich repeat (LRR) domain, in the cytoplasmic region. In addition we
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performed preliminary studies to determine the intercellular localization of any CXCL16 CTF.
After performing subcellular fractionation on RKO cells in culture, we performed western blot
analysis using an antibody recognizing an epitope on the cytoplasmic domain of CXCL16. We
found CXCL16 in the chromatin associated nuclear fraction. Although these data are
preliminary, they provide insight into the roles of CXCL16 CTF, after further processing. These
data are also suggestive that CXCL16 may be involved in multiple signaling pathways. CXCL16
has been found upregulated in brain and pancreatic cancers, where it is not found in normal
tissue of this type 8, 12. In addition to being found upregulated in colon cancer cells4, 16, CXCL16
has been found to be a prognostic factor in prostate cancer 9. These data highlight CXCL16 as an
interesting target for studies in colorectal cancer progression inclusive of cancer progression as a
whole. We speculate that involvement of CXCL16 on increased proliferation of cancer cells may
include intercellular signaling by CXCL16 CTFs. Studies to determine the involvement of
CXCL16 on other proliferative pathways would further elucidate the role of CXCL16 and
highlight the multifunctional capacity of CXCL16 as a representative of the chemokine family of
immune molecules, as a whole.
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